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AbstrAct:
The p53 family transcription factors p53, p63 and p73 make diverse contributions in 
development and cancer. Mutation or deletion of p53 is observed in the majority of 
human cancers. In contrast, p63 and p73 are not lost in cancer but mediate distinct 
genetic roles in normal and tumor-specific contexts: p73 promotes genome stability 
and mediates chemosensitivity, while p63 largely lacks these p53-like functions 
and instead promotes proliferation and cell survival. We recently uncovered a 
mechanism which maintains p63/p73 homeostasis within the epithelium through 
direct transcriptional regulation of microRNAs (miRs). We discovered that several 
of the top p63-regulated miRs target p73 for inhibition, including miR-193a-5p, a 
direct p63/p73 transcriptional target which is repressed by p63 and activated by 
p73 both in vitro and in vivo. The resulting feed-forward circuit involving p63, miR-
193a-5p and p73 controls p73 levels, cell viability and DNA damage susceptibility 
in certain cancers including squamous cell carcinoma. Here, we discuss the 
evolutionary implications of this regulatory circuit, which may point to a general 
mechanism of miR-mediated cross-talk within transcription factor gene families. 
Additionally, we suggest that inducible chemoresistance mediated by this miR-
dependent mechanism might be an attractive target for therapeutic intervention. 
the p53 fAmily: collAborAtion 
And competition in epitheliAl 
cAncers
The p53 gene is the prototypical human tumor 
suppressor and is mutated or lost in the majority of 
human cancers. Loss of p53 transcription factor function 
in cancer reflects the diverse contribution of this protein 
to the DNA damage response, cell cycle regulation, cell 
survival and many other functions [1]. Two p53-related 
genes, p63 and p73, are expressed in mammals, but unlike 
p53  neither  of  these  genes  exhibits  frequent  somatic 
mutation in cancer [2, 3]. Both p63 and p73 are expressed 
as  two  predominant  isoform  classes  resulting  from 
alternative promoter usage: the TAp63/TAp73 isoforms 
contain an N-terminal transactivation domain and most 
resemble p53, while the ∆Np63/∆Np73 isoforms exhibit 
a truncated N-terminus. Additional isoforms of p63 and 
p73 are generated through alternative C-terminal mRNA 
splicing  [2,  4]. While TAp63/TAp73  isoforms  mediate 
predominantly transcriptional activation, ∆Np63/∆Np73 
isoforms  function  as  transcriptional  activators  and 
repressors of distinct sets of transcriptional target genes 
[3]. Genetic and biochemical studies have identified p53-
like  functions  for  p73  in  the  maintenance  of  genomic 
integrity and regulation of apoptosis [5, 6]. In contrast, p63 
functions to maintain cellular regenerative proliferation 
and survival of stratified epithelia [7, 8]. 
Both  p63  and  p73  exhibit  isoform-specific 
expression  and  functions  in  human  cancer  [3].  In 
squamous  cell  carcinoma  (SCC)  and  certain  breast 
cancers the predominant p63 isoform is ∆Np63α, which 
is closely linked to cell survival and adhesion signaling, 
while in these same tumors pro-apoptotic TAp73 isoforms 
predominate  [9,  10].  Multiple  functional  interactions 
occur between these isoforms and are important for tumor 
maintenance. These include direct physical interaction 
between  p63  and  p73  through  their  homologous 
oligomerization domains, and regulation of shared 
transcriptional target genes through direct promoter Oncotarget 2011; 2:  259 - 264 260 www.impactjournals.com/oncotarget
binding mediated via highly homologous DNA binding 
domains [4, 11]. In SCC and some triple-negative breast 
cancers (TNBC, so-called because they lack expression 
of estrogen receptor, progesterone receptor, and amplified 
HER2),  tumor  cell  survival  depends  on  the  ability  of 
∆Np63α to physically associate with TAp73 and thereby 
abrogate p73-dependent apoptosis [11, 12]. ∆Np63α also 
binds directly in a repressive complex at p73-regulated 
pro-apoptotic  gene  promoters,  providing  an  additional 
mode of functional p73 suppression [13]. The therapeutic 
relevance of these findings is evidenced by the ability of 
cisplatin chemotherapy, a mainstay of SCC treatment and 
an emerging agent for TNBC therapy, to target ∆Np63 
for degradation and TAp73 for phosphorylation, thereby 
activating the p73-dependent pro-apoptotic program [12, 
14]. Based on these findings, studying mechanisms which 
regulate p63/p73 expression and function in these tumors 
may uncover new therapeutic opportunities. 
mir-dependent regulAtion And 
the p53 fAmily 
MicroRNAs  (miRs)  are  small  non-coding  RNAs 
that  function  as  post-transcriptional  regulators  of  gene 
and protein expression. Several miRs have recently been 
linked to the p53 family. In particular, miR-34a is a direct 
transcriptional  target  of  p53  which  contributes  to  p53-
dependent functions through interaction with p53-regulated 
mRNAs [15-17]. Additionally, multiple miRs have now 
been shown to target p53 itself for inhibition, suggesting 
these miRs may function as oncogenes [18, 19]. TAp63 
isoforms function as metastasis suppressors in certain 
cancers in part through regulation of a miR-dependent 
program [20], and at least one miR has been identified to 
control p63 itself and to modulate its developmental role 
[21]. As evidenced by these examples and as discussed in 
more detail below, an emerging consensus is that miRs 
are  particularly  prominent  within  regulatory  circuits 
controlling  transcription  factor  functions. Although  we 
are  only  beginning  to  uncover  their  complexity,  such 
circuits may be particularly important within transcription 
factor gene families. 
A mir-mediAted mechAnism for 
cross-tAlk within the p53 fAmily
In order to identify p63-regulated miRs we performed 
global miR expression profiling following p63 ablation 
in human squamous cell carcinoma (SCC) cells, which 
express high levels of endogenous ΔNp63α. Surprisingly, 
we  observed  that  three  of  the  top  ten  most  highly-
regulated  miRs,  miR-193a-5p,  miR-602,  and  miR-765, 
were predicted to target the p73 3’UTR [14]. Each of these 
miRs was induced following p63 knockdown, suggesting 
a miR-dependent mechanism for p63 to activate p73. We 
initially validated this proposed model by demonstrating 
that p63 controlled gene expression via the p73 3’UTR 
in a manner dependent upon Drosha, an RNase III-type 
endonuclease required for miR nuclear processing. We next 
focused on one of these miRs, miR-193a-5p (designated 
miR-193* in mouse; hereafter both human and mouse are 
referred to as miR-193a). We confirmed direct regulation 
of the p73 3’UTR by a transfected miR-193a mimic, using 
UTR constructs in which we engineered mutations in the 
predicted seed binding sequences and showing that these 
abolished miR-dependent regulation. In order to establish 
p73 regulation by endogenous miR-193a we introduced a 
miR-193a antagomir (miR inhibitor), which also showed 
the expected UTR-dependent regulation of p73 dependent 
upon the specific miR-193a seed binding sequences [14]. 
We were then interested to know whether regulation 
of  miR-193a  by  ∆Np63α  was  a  direct  transcriptional 
effect. We therefore used chromatin immunoprecipitation 
(ChIP) to map a p63 binding site with the miR-193a locus, 
and we showed using reporter assays that the canonical 
p53  family  binding  sequence  within  this  p63-bound 
region  was  required  for  p63  dependent  suppression  of 
this miR. Remarkably, we also observed direct binding 
of p73, as well as TAp73-dependent regulation of miR-
193a following cisplatin chemotherapy treatment, which 
is  known  to  induce  ∆Np63α degradation and TAp73 
activation [14]. Collectively, these findings suggested a 
feed-forward  loop  whereby  ∆Np63α  expression  would 
suppress miR-193a and thereby increase TAp73 levels, 
while  TAp73  would  be  involved  in  negative  feedback 
regulation via its own 3’UTR and miR-193a (Figure 1). 
These  predictions  were  all  experimentally  validated. 
Furthermore, we provided evidence for the validity of this 
regulatory mechanism in primary SCC specimens, which 
show  variable  levels  of  ∆Np63α  overexpression,  by 
demonstrating a significant inverse correlation between 
∆Np63 and miR-193a levels, and a positive correlation 
between ∆Np63 and TAp73 levels [14]. 
inducible chemoresistAnce 
through p63/p73 feed-forwArd 
regulAtion
Given  that  this  miR-dependent  circuit  converged 
on regulation of p73, we next tested the contribution of 
miR-193a in a key physiologic context for p73 function: 
the response to cisplatin, which as noted above is both an 
inhibitor of ∆Np63α and a specific activator of TAp73-
dependent transcription and cell death [12, 22]. As noted 
above,  miR-193a  was  induced  by  TAp73  in  response 
to  cisplatin,  and  consistent  with  our  proposed  model 
we  observed  that  a  miR-193a  antagomir  substantially 
increased  chemosensitivity  in  response  to  cisplatin. 
Moreover,  we  found  that  this  effect  was  specifically 
attributable to regulation of TAp73. Thus, the difference 
in chemosensitivity observed in control versus antagomir-Oncotarget 2011; 2:  259 - 264 261 www.impactjournals.com/oncotarget
treated cells was correlated with induction of TAp73 pro-
apoptotic transcriptional target genes, and this difference 
was abolished when TAp73 knockdown was performed 
prior  to  cisplatin  treatment  [14].  Taken  together,  these 
findings  argue  that  induction  of  miR-193a  through  the 
p63  and  p73-dependent  effects  of  cisplatin  limits  p73-
dependent  chemosensitivity  through  direct  feedback 
inhibition.
To  determine  whether  these  findings  could  be 
both  generalized  and  validated  in  vivo  we  tested  the 
contribution of miR-193a to chemosensitivity in a mouse 
model  of  SCC.  This  model  recapitulates  the  features 
of  human  SCC,  including  high-level  p63  expression, 
squamous differentiation, and metastasis to local lymph 
nodes  [14].  Primary  SCC  tumors  were  disaggregated, 
then re-implanted into multiple mice in the presence of 
a miR-193a antagomir or control, followed by treatment 
with  cisplatin  or  vehicle.  Notably,  we  observed  that 
inhibition  of  miR-193a  alone  was  sufficient  to  inhibit 
tumor  growth,  in  keeping  with  its  ability  to  potentiate 
the  pro-apoptotic  activity  of TAp73.  Most  importantly, 
however, miR-193a inhibition had a dramatic impact on 
chemosensitivity to cisplatin. Indeed, a cisplatin dose that 
alone had no significant effect on tumor progression in 
control antagomir-treated tumors nevertheless completely 
abolished tumor growth in miR-193a antagomir-treated 
tumors  [14].  These  experiments  therefore  provide 
tantalizing proof-of-principle for targeting miR expression 
as  a  means  to  enhance  chemosensitivity  in  SCC  and 
potentially other tumors, including TNBC, which express 
p63 and p73. 
potentiAl physiologic And 
evolutionAry role of p63/p73 
feed-forwArd regulAtion
The  endogenous  regulatory  circuit  we  have 
identified  involves  a  negative  feed-forward  loop  from 
p63  to  p73  (Figure).  While  feed-forward  transcription 
factor regulatory networks involving miRs are proposed 
to be a recurrent motif in mammalian cells [23], to our 
knowledge only one example, involving c-Myc and E2F1, 
has  been  fully  experimentally  validated  [24,  25].  The 
p63/p73 circuit is unique in involving two transcription 
factors which are members of a conserved gene family. 
This  circuit  is  also  noteworthy  as  the  first  example  of 
such a regulatory motif implicating three levels of direct 
regulation: transcriptional regulation of the miR by p63 
and p73; post-transcriptional regulation of p73 by the miR, 
and post-translational regulation of p73 activity by p63 
through both direct protein interaction and competition at 
shared promoter elements [9, 11, 12, 26]. The rationale 
for such complex circuitry has been proposed to involve 
the  dampening  of  random  fluctuations  in  activation/
expression  of  the  involved  transcription  factors,  which 
thereby  prevents  inappropriate  state  switching  (e.g. 
from proliferation to growth arrest or cell death) [23]. 
Whereas  the  c-Myc/E2F1  loop  is  thought  to  maintain 
stable  expression  of  E2F1,  we  provide  evidence  that 
the p63/p73 circuit by virtue of its distinct mechanism 
serves to maintain balanced co-expression of these two 
factors. Clearly, an imbalance could produce disastrous 
consequences,  given  the  essential  and  often  opposing 
figure 1: A mir-mediated negative feed-forward loop maintains p63/p73 homeostasis in the epithelium.
A. Proposed miR-mediated feed-forward circuit. P63 is a transcriptional repressor of miRs that target p73 for inhibition. One of these miRs, 
miR-193a, is a direct transcriptional target repressed by p63 and activated by p73. P63 also inhibits p73 function by direct physical interaction 
and by binding to shared promoter elements. This p63/p73 circuit is unique in involving two transcription factors which are members of a 
conserved gene family. Additionally, it is remarkable for implicating three levels of direct regulation: transcriptional regulation by p63 and p73 
of the miR; post-transcriptional regulation by the miR of p73, and post-translational regulation by p63 of p73 activity. 
b. Schematic expression levels of p63, p73 and miR-193a in basal cells of stratified squamous epithelium (normal) and squamous cell 
carcinoma (tumor). Both p63 and p73 are up-regulated in tumors relative to normal cells. Increased p63 expression in tumors mediates miR-
193a repression, which in turn contributes to increased p73 mRNA and thereby maintains a balanced p63/p73 ratio. Disruption of the network 
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roles of p63 and p73 in cellular proliferation and survival 
(∆Np63α), and apoptosis and tumor suppression (TAp73) 
[5, 27]. Confirming the importance of this miR-dependent 
homeostatic mechanism, we found that cell viability is 
compromised when endogenous miR-193a is inhibited, 
and we confirmed that this is a TAp73-dependent effect. 
Furthermore,  we  show  that  the  p63/p73-dependent 
apoptotic response to chemotherapy is dramatically 
perturbed in the absence of miR-193a, leading to enhanced 
cytotoxicity both in vitro and in vivo. 
While our findings provide a unique example of a miR-
mediated regulatory circuit within a transcription factor 
gene family, it is conceivable that such miR-dependent 
mechanisms for feedback and feed-forward regulation may 
modulate the function of other such families. For example, 
transcriptional co-regulation of common set of miRs by 
different members of a transcription factor gene family 
might be relatively common, while feedback regulation 
to one of the involved factors might facilitate functional 
divergence among closely-related family members during 
evolution. Indeed, the stability provided by miR-mediated 
circuits has been proposed to contribute to “evolvability” 
by  buffering  the  phenotypic  consequences  of  genetic 
variation [28]. In this regard it is of note that the more 
homologous  family  members  p63  and  p73  participate 
in the miR-193a regulatory circuit, while p53, which is 
more distant in both in its sequence and function, is not a 
direct participant. Additional examples of miR-mediated 
network  motifs  involving  a  single  transcription  factor 
family will no doubt be uncovered, and they may provide 
new insights into the contribution of non-coding RNAs to 
developmental homeostasis. 
therApeutic implicAtions of mir-
dependent p63/p73 regulAtion 
The critical role of p53 as a tumor suppressor has 
focused  attention  on  various  means  to  target  the  p53 
pathway as a therapeutic strategy [29]. Unfortunately, the 
loss or mutation of p53 observed in many cancers presents 
substantial challenges to efforts aimed at activating p53 
itself  in  tumors.  Furthermore,  tumors  harboring  p53 
loss of function are in general associated with treatment 
resistance  and  a  relatively  poorer  prognosis.  We  and 
others have observed that a subset of tumors exhibiting 
mutational activation of p53 retain or indeed up-regulate 
pro-apoptotic isoforms of p73 [9, 30]. This tumor-specific 
TAp73 expression may represent a response to ongoing 
and/or  unrepaired  spontaneous  DNA  damage  in  tumor 
cells. Despite TAp73 expression, however, tumors utilize 
a variety of mechanisms to suppress TAp73 activity and 
thereby avoid its lethal consequences [3]. Nevertheless, 
TAp73 can be activated by chemotherapy and other DNA 
damaging agents, triggering a TAp73-dependent apoptotic 
response. The ability of certain DNA damaging agents 
including  cisplatin  to  activate  TAp73  may  therefore 
explain the correlation of p73 levels with chemotherapy 
response in a variety of tumor-specific contexts [31, 32]. 
Given these observations, our discovery that a miR-
dependent mechanism controls p73 levels and activity in 
certain cancers provides a new means to target the TAp73-
dependent apoptotic response for tumor-specific killing. 
The finding that this miR participates in a feed-forward 
regulatory loop with ∆Np63α suggests particular relevance 
for this mechanism in epithelial tumors which co-express 
these factors, including SCC and TNBC. Specifically, our 
data  suggest  that  TAp73-dependent  induction  of  miR-
193a following chemotherapy functions as a mechanism 
of  inducible  chemoresistance  by  limiting  the  TAp73-
mediated  DNA  damage  response.  In  keeping  with  this 
hypothesis, we demonstrate using our orthotopic tumor 
model that a completely ineffective chemotherapy dose 
can completely block tumor progression when combined 
with  miR-193a  inhibition.  Importantly,  complementary 
in  vitro  experiments  show  that  the  potentiation  of 
chemosensitivity following miR inhibition is a TAp73-
dependent  effect.  Cisplatin  was  the  chemotherapy 
agent of choice for these experiments, owing both to its 
specific activation of TAp73 and to its use as a mainstay 
of  SCC  therapy  and  a  potentially  important  agent  for 
treatment of TNBC [31, 33]. Thus, targeting miR-193a 
for chemosensitization may represent an attractive future 
treatment strategy. 
Perhaps  even  more  exciting  from  a  therapeutic 
standpoint,  our  findings  suggest  that  TAp73  activation 
through  miR  inhibition  may  be  associated  with  a 
therapeutic effect even in the absence of DNA damaging 
chemotherapy. This  observation  is  in  line  with  a  body 
of  work  by  our  group  and  others  demonstrating  that 
activation  of  TAp73  may  represent  a  common  stress 
response mechanism, particularly in p53-mutant tumors. 
For example, recent work suggests that in addition to DNA 
damage, TAp73 is activated in response to growth factor 
withdrawal and metabolic stress [34, 35]. Given that these 
pathways are already being selectively targeted in cancer 
therapy, the potential to enhance the lethal response to such 
therapies through concurrent miR suppression leading to 
TAp73 hyper-activation is quite appealing. 
A  conceptually  similar  combination  might  be 
envisioned  between  miR-193a  inhibition  and  the  new 
generation of targeted therapies that aim to disable DNA 
repair itself. The prototype of these drugs are inhibitors of 
poly ADP(ribose) polymerase (PARP), enzymes required 
for  single-strand  break  and  base-excision  repair  [36]. 
Combinations of PARP inhibitors with DNA damaging 
chemotherapy are already showing early promise in the 
treatment of TNBC [37, 38]. Activation of TAp73 may 
be involved in the response to unrepaired DNA damage 
in at least a subset of these tumors. Additionally, PARP 
inhibitors  are  known  to  disable  repair  of  spontaneous 
DNA damage in the absence of chemotherapy, an effect 
which is likely to trigger TAp73 activation. Therefore, it Oncotarget 2011; 2:  259 - 264 263 www.impactjournals.com/oncotarget
is attractive to speculate that the combination of a PARP 
inhibitor with miR-193a inhibition in these tumors might 
be  sufficient  to  induce  a  TAp73-dependent  therapeutic 
response in the absence of chemotherapy. In theory, such a 
combination might be more tumor-selective and less toxic 
than a PARP inhibitor/chemotherapy combination, owing 
in part to high levels of TAp73 expressed in some tumors 
relative to normal cells.
conclusions
The prominent role of miRs as regulators of gene 
expression, and their deregulation in human cancer 
provide hope that these molecules may serve as important 
tools for cancer detection, diagnosis and prognostication. 
Our  work  demonstrates  in  addition  how  uncovering 
the  detailed  functional  contribution  of  miRs  in  cancer 
could  open  the  door  to  a  new  class  of  miR-targeted 
cancer  therapies.  We  have  revealed  a  central  role  for 
the  p63-regulated  miR-193a  in  maintaining  p63/p73 
homeostasis  within  the  epithelium.  Selective  targeting 
of  this  miR  enhances  chemosensitivity,  and  may  have 
future applications in modulating the response to targeted 
therapeutics in selected cancer subtypes. Understanding 
the complex regulatory circuits in which miRs function, 
as well as their tumor-specific context, will be essential 
for realizing the promise of miRs in cancer diagnosis and 
therapy. 
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